Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Thermosensitive Pluronic® F127-Based in situ gel formulation containing nanoparticles for the sustained delivery of paclitaxel

Sedat Unal, Merve Celik Tekeli, Osman Dogan, Yesim Aktas.




Abstract

Bone metastasis is one of the most encountered complications among cancer patients and majority of cancer types has led to bone metastasis. Paclitaxel (PCX) is an anticancer agent commonly used in cancer treatment. However, its clinical use is restricted owing to poor water solubility. PCL NPs were investigated to cope with solubility problem of PCX. The size, polydispersity index and zeta potential of PCL were 383.8±2.4 nm, 0.253±0.122 and +51.3±6.1 mV, respectively. The PCX encapsulation efficiency was 77.2±2.1%. Subsequently, in situ gellling system was prepared by using different Pluronic F-127 concentration in order to determine the optimum ratio. İn situ gel formulation containing 20% Pluronic F-127 was selected as the optimum formulation and subjected to characterization tests. The viscosity of in situ gelling system with CS/PCX-PCL NPs at room temperature (25 °C±0.1) and at body temperature (37 °C±0.1) were found 137.00 ±3.05 cP and 890.30 ±89.61 cP at 100 rpm, respectively. According to the release results, in situ gel provided prolonged release profile compared to PCL NPs alone. Consequently, in situ gel containing CS/PCX-PCL NP elucidated in detail is a promising approach for locally applicable injectable systems.

Key words: Cancer, nanoparticles, paclitaxel, in situ gel, drug release






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.